Inhibrx Biosciences, Inc. (INBX) Free Cash Flow
Inhibrx Biosciences, Inc. (INBX) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2020-12-31 | -$49.33M |
| 2021-12-31 | -$81.13M |
| 2022-12-31 | -$115.99M |
| 2023-12-31 | -$197.90M |
| 2024-12-31 | -$197.01M |
| 2025-12-31 | -$129.82M |
How INBX compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| AXSM | Axsome Therapeutics Inc. | -$93.89M |
| VNDA | Vanda Pharmaceuticals Inc. | -$110.44M |
| VYGR | Voyager Therapeutics Inc. | -$135.06M |
| VSTM | Verastem Inc. | -$147.13M |
| CELC | Celcuity Inc. | -$153.53M |
These are five companies in the same sector as INBX with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Inhibrx Biosciences, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("INBX", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | INBX | $123.41 | -0.42% | 0.24M |
| 3 | ||||
| 4 | ||||
| 5 |